- Home
- ARQT vs KYMR Comparison
ARQT vs KYMR Comparison
Compare ARQT & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- KYMR
- Stock Information
- Founded
- ARQT 2016
- KYMR 2015
- Country
- ARQT United States
- KYMR United States
- Employees
- ARQT N/A
- KYMR N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- KYMR Medicinal Chemicals and Botanical Products
- Sector
- ARQT Health Care
- KYMR Health Care
- Exchange
- ARQT Nasdaq
- KYMR Nasdaq
- Market Cap
- ARQT 1.7B
- KYMR 1.8B
- IPO Year
- ARQT 2020
- KYMR 2020
- Fundamental
- Price
- ARQT $13.04
- KYMR $29.64
- Analyst Decision
- ARQT Strong Buy
- KYMR Buy
- Analyst Count
- ARQT 6
- KYMR 15
- Target Price
- ARQT $18.80
- KYMR $55.47
- AVG Volume (30 Days)
- ARQT 2.1M
- KYMR 622.7K
- Earning Date
- ARQT 05-06-2025
- KYMR 05-09-2025
- Dividend Yield
- ARQT N/A
- KYMR N/A
- EPS Growth
- ARQT N/A
- KYMR N/A
- EPS
- ARQT N/A
- KYMR N/A
- Revenue
- ARQT $212,819,000.00
- KYMR $58,885,000.00
- Revenue This Year
- ARQT $61.15
- KYMR $32.80
- Revenue Next Year
- ARQT $37.98
- KYMR $8.88
- P/E Ratio
- ARQT N/A
- KYMR N/A
- Revenue Growth
- ARQT 100.03
- KYMR N/A
- 52 Week Low
- ARQT $6.99
- KYMR $19.45
- 52 Week High
- ARQT $17.75
- KYMR $53.27
- Technical
- Relative Strength Index (RSI)
- ARQT 40.51
- KYMR 48.27
- Support Level
- ARQT $13.27
- KYMR $28.06
- Resistance Level
- ARQT $14.30
- KYMR $30.28
- Average True Range (ATR)
- ARQT 0.71
- KYMR 1.65
- MACD
- ARQT -0.07
- KYMR -0.19
- Stochastic Oscillator
- ARQT 10.94
- KYMR 27.96
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.